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 TSG-6 suppresses the development of
atherosclerosis by decreasing inﬂammatory
responses of endothelial cells and
macrophages, endothelial proliferation,
macrophage foam cell formation, and VSMC
migration and proliferation.
 TSG-6 also contributes to plaque stability
by extracellular matrix production in the
ﬁbrous cap.
 TSG-6 is expected to emerge as a new line
of therapy against atherosclerosis and CAD.
 This study also provides insights into the
potential use of TSG-6 as a biomarker for
CAD.
 These ﬁndings may strengthen the clinical
utility of TSG-6 in the diagnosis and
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495SUMMARYTumor necrosis factor–stimulated gene-6 (TSG-6), an anti-inﬂammatory protein, was shown to be localized in the
neointima of injury-induced rat arteries. However, the modulatory effect of TSG-6 on atherogenesis has not yet been
reported. We aimed to evaluate the atheroprotective effects of TSG-6 on human endothelial cells (HECs), human
monocyte-derived macrophages (HMDMs), human aortic smooth muscle cells (HASMCs) in vitro, and aortic lesions in
apolipoprotein E–deﬁcient mice, along with expression levels of TSG-6 in coronary lesions and plasma from patients with
coronary artery disease (CAD). TSG-6 was abundantly expressed in HECs, HMDMs, and HASMCs in vitro. TSG-6 signiﬁ-
cantly suppressed cell proliferation and lipopolysaccharide-induced up-regulation of monocyte chemotactic protein-1,
intercellular adhesion molecule-1, and vascular adhesion molecule-1 in HECs. TSG-6 signiﬁcantly suppressed inﬂamma-
tory M1 phenotype and suppressed oxidized low-density lipoprotein–induced foam cell formation associated with
down-regulation of CD36 and acyl-CoA:cholesterol acyltransferase-1 in HMDMs. In HASMCs, TSG-6 signiﬁcantly
suppressed migration and proliferation, but increased collagen-1 and -3 expressions. Four-week infusion of TSG-6
into apolipoprotein E–deﬁcient mice signiﬁcantly retarded the development of aortic atherosclerotic lesions with
decreased vascular inﬂammation, monocyte/macrophage, and SMC contents and increased collagen ﬁbers. In addition,
it decreased peritoneal M1 macrophages with down-regulation of inﬂammatory molecules and lowered plasma
total cholesterol levels. In patients with CAD, plasma TSG-6 levels were signiﬁcantly increased, and TSG-6 was
highly expressed in the ﬁbrous cap within coronary atherosclerotic plaques. These results suggest that TSG-6
contributes to the prevention and stability of atherosclerotic plaques. Thus, TSG-6 may serve as a novel therapeutic
target for CAD. (J Am Coll Cardiol Basic Trans Science 2016;1:494–509) © 2016 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).AB BR E V I A T I O N S
AND ACRONYM S
ABCA1 = ATP-binding cassette
transporter A1
ACAT1 = acyl-CoA:cholesterol
acyltransferase-1
AngII = angiotensin II
ApoE/ = apolipoprotein E
deﬁcient
CAD = coronary artery disease
ECM = extracellular matrix
HASMC = human aortic smooth
muscle cell
HMDM = human monocyte-
derived macrophage
HUVEC = human umbilical vein
endothelial cell
MMP = matrix metalloproteinase
oxLDL = oxidized low-density
lipoprotein
TIMP = tissue inhibitor of
metalloproteinase
TSG = tumor necrosis factor
stimulated gene
VSMC = vascular smooth
muscle cellT umor necrosis factor–stimulated gene (TSG)-6 is a 35-kDa secreted glycoprotein that hasbeen shown to exert anti-inﬂammatory
effects in experimental models of arthritis, acute
myocardial infarction, and acute cerebral infarction
(1–4). TSG-6 is not usually expressed but is rapidly
up-regulated in many different cell types, including
monocytes, ﬁbroblasts, vascular smooth muscle cells
(VSMCs), synoviocytes, chondrocytes, and proximal
tubular epithelial cells by inﬂammatory mediators
such as interleukin (IL)-1, tumor necrosis factor
(TNF)-a, lipopolysaccharide (LPS), and prostaglandin
E2 (1,5–7). TSG-6 inhibits leukocyte adhesion onto
the vascular wall and leukocyte migration (8,9). In
addition, TSG-6 down-regulates toll-like receptor-2/
nuclear factor (NF)-kB and up-regulates cyclooxyge-
nase (COX)-2 in mouse macrophages (10,11). Although
TSC-6 was shown to be localized in rat neointima af-
ter arterial injury and rabbit carotid atherosclerotic
plaques (12,13), there have been no previous reports
regarding its direct effect on atherogenesis.
Atherosclerosis is a chronic inﬂammatory
response to arterial wall injuries (14). Endothelial
inﬂammation stimulates the production of proin-
ﬂammatory cytokines and molecules such as IL-6,
monocyte chemotactic protein (MCP)-1, intercel-
lular adhesion molecule (ICAM)-1, vascular adhesion
molecule (VCAM)-1, and E-selectin in endothelial
cells (ECs), and monocyte adhesion and inﬁltrationinto the neointima lesion (14). Macrophage foam cells
participate in proinﬂammatory and anti-inﬂammatory
responses via transition to M1 and M2 phenotypes by
releasing and removing inﬂammatory media-
tors, such as TNF-a, IL-6, and oxidized
low-density lipoprotein (oxLDL), within the
arterial intima (15). Foam cell formation is
characterized by the intracytoplasmic
accumulation of cholesterol ester, which is
dependent on the homeostatic balance
between the uptake of oxLDL via CD36, the
efﬂux of free cholesterol (FC) controlled by
the ATP-binding cassette transporter A1
(ABCA1), and cholesterol esteriﬁcation by acyl
CoA:cholesterol acyltransferase-1 (ACAT1)
(16,17). Apart from accumulation of macro-
phage foam cells, the migration and prolifera-
tion of VSMCs, EC proliferation, and the
production of extracellular matrix (ECM)
components such as collagen, matrix metal-
loproteinases (MMPs), tissue inhibitor of met-
alloproteinases (TIMPs), ﬁbronectin, and
elastin contribute to the progression of the
atherosclerotic plaque (14,18).
In the present study, we assessed the
suppressive effects of TSG-6 on the
inﬂammatory responses in human ECs
and human monocyte-derived macro-
phages (HMDMs); foam cell formation; the
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496migration, proliferation, and ECM production in
human VSMCs in vitro; and the development of
atherosclerotic lesions in an apolipoprotein E-deﬁ-
cient (ApoE/) mouse model in vivo. Further, we
investigated TSG-6 expression in coronary lesions
and its plasma levels in patients with coronary ar-
tery disease (CAD).
METHODS
SAMPLE COLLECTION OF HUMAN BLOOD AND
CORONARY ATHEROSCLEROTIC LESIONS. This
study was conducted according to the principles of
the Declaration of Helsinki and approved by the
Ethics Committees of Showa University and Tokyo
University of Pharmacy and Life Sciences. Written
informed consent was obtained from a total of 182
participants before enrollment. Blood was collected
from 135 patients with acute coronary syndrome
hospitalized at Showa University Hospital for emer-
gency coronary catheterization (102 men, 33 women;
age 40 to 96 years) and 47 non-CAD subjects (32 men,
15 women; age 21 to 79 years). The patients with acute
coronary syndrome included 103 patients with acute
myocardial infarction and 32 patients with unstable
angina pectoris. The non-CAD subjects included 23
healthy volunteers and 24 patients with mild hyper-
tension, diabetes, or dyslipidemia. Infections and
inﬂammatory diseases were excluded from subjects
by history and routine laboratory examination
because these are known to increase plasma TSG-6
levels (1,5). Plasma TSG-6 levels were measured by
enzyme-linked immunosorbent assay (ELISA) (human
TSG-6 ELISA kit, Cusabio Biotech, Wuhan, China).
Buffered 10% formalin-ﬁxed parafﬁn-embedded
human coronary artery specimens from archive col-
lections of the National Cerebral and Cardiovascular
Center were used for immunohistochemistry. The
serial thin cross sections (3 to 4 mm) of stenotic and
nonstenotic coronary arteries from 13 patients with a
history of myocardial infarction (9 men, 4 women; age
60 to 87 years) and of normal coronary arteries from 4
patients with dilated cardiomyopathy (4men; age 19 to
39 years) were stained with hematoxylin-eosin and
Elastica van Gieson (19). Immunohistochemistry was
performed on deparafﬁnized glass slides by the auto-
mated immunostainer BOND-III-TM (Leica Bio-
systems, Newcastle, United Kingdom). Polyclonal
rabbit antibodies for human TSG-6 (LifeSpan Bio-
Sciences, Seattle, Washington) or von Willebrand fac-
tor and monoclonal mouse antibodies for human
macrophage (CD68) or a-smooth muscle actin (a-SMA)
(DAKO, Tokyo, Japan) were used as a primary antibody
(19). The detection kit as a secondary antibody wasthe Bond Polymer Reﬁne Detection (DS9800, Leica
Biosystems); it involved incubation with post-primary
for 8 min, polymer for 8 min, DAB for 10 min, and
hematoxylin for 5 min. Masson’s Trichrome staining
for collagen ﬁbers was also performed (19).
HUMAN MONOCYTE PRIMARY CULTURE. Human
peripheral mononuclear cells were isolated from the
blood of 20 healthy volunteers (10 men, 10 women;
age 20 to 24 years). Monocytes puriﬁed using anti-
CD14 antibody-conjugated magnetic microbeads
(Miltenyi Biotec, Auburn, California) were seeded
onto 3.5-cm dishes (1  106 cells per 1 ml/dish) for
cholesterol esteriﬁcation assay and immunoblotting
analysis (19–23). Cells were incubated at 37C in 5%
CO2 for 7 days with the indicated concentrations of
human TSG-6 (R&D Systems, Minneapolis, Minne-
sota) in RPMI-1640 medium (Sigma, St. Louis, Mis-
souri) supplemented with 10% human serum, 0.05
mg/ml streptomycin, and 50 U/ml penicillin. The
medium in each dish was replaced with fresh medium
containing TSG-6 every 3 days.
CHOLESTEROL ESTERIFICATION ASSAY. HMDMs
differentiated by 10% human serum and the indicated
concentrations of TSG-6 for 7 days were incubated for
19 h with the same concentrations of TSG-6 along
with 50 mg/ml human oxLDL and 0.1 mmol/l [3H]
oleate (PerkinElmer, Yokohama, Japan) conjugated
with bovine serum albumin (19,22,23). Cellular
lipids were extracted, and the radioactivity of
cholesterol-[3H]oleate was determined by thin-layer
chromatography.
ENZYME-LINKED IMMUNOSORBENT ASSAY. HMDMs
differentiated by 10% human serum without TSG-6
were incubated for 26 h in serum-free RPMI-1640
medium with or without 300 ng/ml TSG-6. In culture
supernatants, the concentrations of IL-6 and TNF-a
were measured by ELISA (human IL-6 and human
TNF-a ELISA kits, R&D Systems).
MIGRATION ASSAY. Human aortic smooth muscle
cells (HASMCs) (Lonza, Walkersville, Maryland) at
passage 7 or 8 were seeded onto an 8-well culture slide
(3  103 cells per 200 ml/well). Cells were incubated at
37C in 5% CO2 for 3 to 5 h in smooth muscle cell basal
medium (SmBM) supplemented with SmGM-2 Single-
Quots (5% fetal bovine serum [FBS], 0.1% epidermal
growth factor [EGF], 0.2% ﬁbroblast growth
factor [FGF], 0.1% insulin, and 0.1% gentamicin-
amphotericin B mixture) and were then incubated for
24 h in serum-free SmBM. Subsequently, while cells
were incubated for 15 h in serum-free SmBM with
500 nmol/l angiotensin II (AngII) (Sigma) and/or
300 ng/ml TSG-6, photographs of cells were taken for
the last 5 h at 10-min intervals. The average migration
TABLE 1 Primer Sequences Used for Reverse Transcription
Polymerase Chain Reaction
Gene Primer Sequence (50/30)
Product
Size (bp)
IL-6 Forward ATGAACTCCTTCTCCACAAGCGC 628
Reverse GAAGAGCCCTCAGGCTGGACT
TNF-a Forward CAGAGGGAAGAGTTCCCCAG 325
Reverse CCTTGGTCTGGTAGGAGACG
MCP-1 Forward CAATAGGAAGATCTCAGTGC 189
Reverse GTGTTCAAGTCTTCGGAGTT
ICAM-1 Forward CGACTGGACGACAGGGATTGT 290
Reverse ATTATGACTGCGGCTGCTACC
VCAM-1 Forward TCCCTACCATTGAAGATACTGGAAA 146
Reverse GCTGACCAAGACGGTTGTATCTC
E-selectin Forward CCTACAAGTCCTCTTGTGCCTTC 206
Reverse ACAGGCGAACTTGCACACA
GAPDH Forward ACCACAGTCCATGCCATCAC 451
Reverse TCCACCACCCTGTTGCTGTA
GAPDH ¼ glyceraldehyde-3-dehydrogenase; IL ¼ interleukin; MCP ¼ monocyte
chemotactic protein; ICAM ¼ intercellular adhesion molecule; TNF ¼ tumor
necrosis factor; VCAM ¼ vascular adhesion molecule.
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497distance of 10 cells randomly selected in each well was
measured using a BIOREVO BZ-9000 microscope
(Keyence, Osaka, Japan) (19,22,23).
PROLIFERATION ASSAY. HASMCs or human EA.hy926
ECs at passage 8 or 9 were seeded onto 96-well plates
(1  104 cells per 100 ml/well) and incubated at 37C in
5% CO2 for 24 h in SmBM supplemented with SmGM-2
SingleQuots (Lonza) or in Dulbecco’s Modiﬁed Eagle’s
Medium (Sigma) supplemented with 10% FBS, 1.0 mg/
ml D-glucose/4.5 mg/ml D-glucose, 0.584 mg/ml L-
glutamine, 0.05 mg/ml streptomycin, and 50 U/ml
penicillin. Cells were incubated for 48 h with the
indicated concentrations of TSG-6 with renewal of
each medium. Then, 10 ml of WST-8 solution (Cell
Count Reagent SF, Nacalai Tesque, Kyoto, Japan)
were added to each well (19,22,23). After 1 h of incu-
bation, the amount of formazan product was deter-
mined by measuring the absorbance at 450 nm using
a Sunrise Remote R-microplate reader (Tecan, Kawa-
saki, Japan) (19,22,23).
WESTERN BLOTTING. Aliquots of 20 mg of protein
extracts from HMDMs and HASMCs were separated by
10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and subjected to immunoblotting
with antibodies for TSG-6 (ProteinTech Group, Chi-
cago, Illinois), CD36 (R&D Systems), CD68, ACAT1
(Santa Cruz Biotechnology, Santa Cruz, California),
ABCA1, collagen-1 (Novus Biologicals, Littleton,
Colorado), collagen-3, ﬁbronectin, JNK, a-tubulin,
MMP-2 (GeneTex, Irvine, California), MMP-9 (Eno-
Gene, Atlanta, Georgia), TIMP-2 (Abbiotec, San Diego,
California), elastin, MARCO (Bioss, Woburn, Massa-
chusetts), MRC1 (LifeSpan BioSciences, Seattle,
Washington), phosphoinositide 3-kinase (PI3K), Raf-1
(Abcam, Tokyo, Japan), c-Src (Bioworld Technology,
St. Louis Park, Minnesota), phosphorylated ERK1/2
(Cell Signaling Technology, Tokyo, Japan), NF-kB
(Aviva Systems Biology, San Diego, California), or
b-actin (Sigma) (19–23).
ZYMOGRAPHY. The activities of MMP-2 and -9 were
determined using a gelatin zymography kit (Cosmo
Bio, Tokyo, Japan) (23). The culture supernatants of
HASMCs (15 mg) were mixed with 5 ml of sample buffer
and fractionated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis using 0.1%
gelatin. After electrophoresis, the gel was washed
with renaturing buffer (2% Triton X-100) for 1 h.
The gel was incubated for 20 h at 37C in a reaction
buffer (1% Triton X-100) and then was stained with
Coomassie brilliant blue (23).
REVERSE TRANSCRIPTION-POLYMERASE CHAIN
REACTION. Human umbilical vein endothelial cells
(HUVECs) (Lonza) at passage 4 to 7 were seeded onto3.5-cm dishes and incubated at 37C in 5% CO2 for 24 h
in endothelial growth basal medium (EBM)–2 sup-
plemented with EGM-2 SingleQuots þ FBS (5% FBS,
0.1% EGF, 0.4% FGF, 0.1% VEGF, 0.1% heparin,
0.04% hydrocortisone, 0.1% R3-IGF-1, and 0.1%
gentamicin-amphotericin B mixture). When cells
reached 60% to 70% conﬂuence, they were incubated
for 30 min with 300 ng/ml TSG-6 and then for 2 h with
1 mg/ml LPS (Sigma) and/or 300 ng/ml TSG-6 (23).
Total ribonucleic acid (RNA) was extracted using a
High Pure RNA Isolation Kit (Roche Diagnostics,
Mannheim, Germany). Complementary DNA was
synthesized from isolated RNA templates with a High
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, California). The messenger
ribonucleic acid (mRNA) of IL-6, TNF-a, MCP-1,
ICAM-1, VCAM-1, E-selectin, and glyceraldehyde-3-
dehydrogenase in 50 ng of each sample were detec-
ted by reverse transcription-polymerase chain
reaction, using GoTaq Green Master Mix (Promega,
Madison, Wisconsin) (23–25). The sequences of the
primers and product sizes are listed in Table 1. The
polymerase chain reaction products were separated
by 2% agarose gel electrophoresis.
ANIMAL EXPERIMENTS. Animal experiments were
performed in accordance with the National Institutes
of Health Guidelines for the Care and Use of Labora-
tory Animals and approved by the Institutional Ani-
mal Care and Use Committee of Tokyo University of
Pharmacy and Life Sciences. A total of 28 male,
spontaneously hyperlipidemic, 9-week-old ApoE/
mice (C57BL/6. KOR/StmSlc-Apoeshl mice) were
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498purchased from Japan SLC Inc. (Hamamatsu, Japan)
and maintained on a normal diet until they reached
the age of 13 weeks. Then, a high-cholesterol diet
(Oriental Yeast, Tokyo, Japan) was started (19,22,23).
Two groups of 17-week-old ApoE/ mice were
infused with saline (vehicle) or TSG-6 (75 ng/kg/min)
(GenWay Biotech, San Diego, California) for 4 weeks
using osmotic mini-pumps (Alzet Model 1002, Durect,
Cupertino, California) (19,22). The doses of TSG-6
were decided on the basis of our preliminary exami-
nations and a previous report (26).
Systolic and diastolic blood pressures were
measured using the indirect tail-cuff method (Kent
Scientiﬁc, Torrington, Connecticut). Four days before
the endpoint of infusion, mice were intraperitoneally
injected with 2 ml of aged-autoclaved thioglycolate
broth to obtain exudate peritoneal macrophages,
which is thought to mimic arterial macrophages pre-
sent in atheroma areas (22,27). Exudate peritoneal
macrophages are widely accepted to use in the
assessment of mouse atherosclerosis (22,27).
At the experimental endpoint (before and 4 weeks
after infusion), the ApoE/ mice were sacriﬁced by
exsanguination (total blood collection) under deep
ether anesthesia (19,21–23). Peritoneal cells were
sampled by needle aspiration (19,21–23). The whole
aorta was immediately washed by perfusion with PBS
and was ﬁxed with 4% formaldehyde (19,21–23). The
aorta was excised from the aortic root to the abdom-
inal area, and the connective and adipose tissues
were carefully removed.
ATHEROSCLEROTIC LESION ASSESSMENT. The entire
aorta lumen surface and cross sections of the aortic
sinus were stained with oil red O for assessment of
atherosclerotic lesion area and plaque size, respec-
tively (19,21–23). In aortic sinus, vascular inﬂamma-
tion, intra-plaque monocyte/macrophage and VSMC
contents, and collagen ﬁbers were visualized by
staining with antibodies for pentraxin-3 (Bioss),
MOMA-2 (Millipore, Billerica, Massachusetts), or
a-SMA (Sigma) and Masson’s Trichrome (Muto Pure
Chemicals, Tokyo, Japan), respectively (19,22,23). The
positive stained areas were traced by an investigator
blind to the treatment and measured using image
analysis software (Adobe Photoshop, San Jose, Cali-
fornia; and NIH ImageJ, Bethesda, Maryland). The
degree of vascular inﬂammation derived from mainly
ECs followed by VSMCs and macrophages was
expressed as a percentage of the pentraxin-3–positive
area relative to the entire cross section of the aortic
wall (21,27).
MOUSE PERITONEAL EXUDATE MACROPHAGE
ASSESSMENT. Peritoneal cells were immediatelysuspended in RPMI-1640 medium supplemented with
10% FBS, 0.05 mg/ml streptomycin, and 50 U/ml
penicillin, and were seeded onto 6-cm dishes (4  106
cells per 2 ml/dish). After incubation for 1 h at 37C in
5% CO2 to allow adhesion, the medium was discarded
to remove nonadherent cells. Adherent macrophages
were immediately harvested after washing the dishes
with PBS twice for immunoblotting with antibodies to
pentraxin-3, MARCO (Bioss), arginase-1, MCP-1, JNK
(GeneTex), COX-2 (Cayman Chemical, Ann Arbor,
Michigan), NF-kB (Aviva Systems Biology), phos-
phorylated ERK1/2 (Cell Signaling Technology), or
b-actin (Sigma) (19,22).
BLOOD SAMPLE MEASUREMENTS. Fasting plasma
glucose and total cholesterol levels were measured by
enzymatic methods (Denka Seiken, Tokyo, Japan)
and high-density lipoprotein (HDL) levels were
measured by a precipitation method (Wako, Osaka,
Japan) (19,21–23). Plasma levels of TSG-6 and
pentraxin-3 were measured by ELISA (Cusabio
Biotech, R&D Systems).
STATISTICAL ANALYSIS. Results are expressed as
mean  SEM for continuous variables and as
percentages for categorical variables. Normal distri-
bution of continuous variables was assessed using
the Kolmogorov-Smirnov test. On the basis of the
normality of the variables, the parametric or the
nonparametric test was chosen as appropriate. Com-
parisons between 2 groups were made using the
unpaired Student t test or the Mann-Whitney U test.
Multiple comparisons were made among $3 groups
using 1-way analysis of variance or the Kruskal-
Wallis test followed by the Bonferroni post-hoc test.
The categorical variables were analyzed using the
chi-square test. Multiple linear regression analysis
was performed to evaluate the predictor variables for
plasma TSG-6 levels. Pearson’s correlation coefﬁcient
was used to evaluate the linear relationship between
plasma TSG-6 levels and other variables. Statistical
analyses were performed using Statview-J version
5.0 (SAS Institute, Cary, North Carolina) and SPSS
version 22.0 (SPSS Inc., Chicago, Illinois). A value of
p < 0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
EXPRESSION OF TSG-6 IN HUMAN VASCULAR CELLS
IN VITRO. TSG-6 was expressed at inﬁnitesimal
levels in human monocytes but at high levels in
HMDMs, HASMCs, and HUVECs (Figure 1A). The in-
dependent experiment that was repeated once more
also conﬁrmed the same results. The results were
consistent with the previous reports (1,5–7).
FIGURE 1 Expression of TSG-6 in Human Vascular Cells and its Effects on Inﬂammatory Response and Proliferation in Human ECs
(A) Aliquots of 40 mg of cellular protein from human monocytes, HMDMs, HASMCs, and HUVECs were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and subjected to immunoblotting analysis for humanTSG-6 and b-actin. Immunoblots are representative
of 2 independent experiments. (B) Proliferation of EA.hy926 ECs was determined by WST-8 assay after 48-h incubation in DMEM containing 2
concentrations of D-glucose (Glc) (1.0 or 4.5 mg/ml) with the indicated concentrations of TSG-6. EA.hy926 ECs cultured in 4.5 mg/ml D-glucose–
conditionedmediumwere stained by hematoxylin eosin. Glc 1.0mg/ml (blue): n¼ 4; *p< 0.005; †p< 0.0005; ‡p< 0.0001 vs. 0 ng/ml of TSG-6.
Glc 4.5 mg/ml (red): n¼ 5; #p< 0.01 vs. 0 ng/ml of TSG-6. (C) HUVECs were pre-treated with or without TSG-6 (300 ng/ml) for 30 min and then
incubated with or without LPS (1 mg/ml) for 2 h. The levels of IL-6, TNF-a, MCP-1, ICAM-1, VCAM-1, E-selectin, and GADPH mRNA expression were
measured by reverse transcription polymerase chain reaction. The graph shows the densitometric data of eachmolecule after normalization relative
toGADPH. n¼ 3 to4; §p¼0.028; ¶p<0.005vs. control;＠p<0.01; &p¼0.028vs. LPS. All values arepresented asmean SEM.EC¼ endothelial
cells; GAPDH¼ glyceraldehyde-3-dehydrogenase; Glc¼ D-glucose;HASMC¼ humanaortic smoothmuscle cell; HMDM¼ humanmonocyte-derived
macrophage; HUVEC ¼ human umbilical vein endothelial cell; ICAM ¼ intercellular adhesion molecule; IL ¼ interleukin; LPS ¼ lipopolysaccharide;
MCP ¼monocyte chemotactic protein; mRNA¼messenger ribonucleic acid; TNF ¼ tumor necrosis factor; TSG¼ tumor necrosis factor–stimulated
gene; VCAM ¼ vascular adhesion molecule.
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499EFFECTS OF TSG-6 ON PROLIFERATION AND
INFLAMMATORY RESPONSE IN HUMAN ECs. In a
normal glucose condition (1.0 mg/ml), TSG-6 at 5 to
300 ng/ml signiﬁcantly suppressed the proliferation of
EA.hy926 ECs, with the maximal reduction by w10%
(Figure 1B). In a high glucose condition (4.5 mg/ml),
TSG-6 signiﬁcantly suppressed the proliferation only
at 300 ng/ml, with a maximal reduction of w25%
(Figure 1B). The micrographs conﬁrmed that the
reduction in cell number was not attributed to death
due to apoptosis and cytotoxicity by 4.5mg/ml glucose
and/or 300 ng/ml TSG-6 (Figure 1B). These observa-
tions suggest that the antiproliferative effects of TSG-6
may be accentuated under the condition of
hyperglycemia-induced endothelial dysfunction.TSG-6 itself had no signiﬁcant effects on mRNA
expressions of IL-6, TNF-a, MCP-1, ICAM-1, VCAM-1,
and E-selectin, but LPS markedly stimulated these
expressions in HUVECs (Figure 1C). However, TSG-6 at
300 ng/ml signiﬁcantly suppressed LPS-induced
mRNA expressions of MCP-1, ICAM-1, and VCAM-1,
but not IL-6, TNF-a, and E-selectin, in HUVECs
(Figure 1C).
EFFECTS OF TSG-6 ON INFLAMMATORY PHENOTYPE
AND CYTOKINE SECRETION IN HMDMs. After 3 to 6
days of primary culture, the differentiation of human
monocytes into HMDMs was conﬁrmed by the
increased protein expression of CD68, a macrophage
differentiationmarker (Figure 2A). TSG-6 did not affect
FIGURE 2 Effects of TSG-6 on Inﬂammatory Phenotypes, Cytokine Secretion, Foam Cell Formation, and Related Protein
Expression in HMDMs
(A) Human monocytes were incubated for the indicated times in RPMI-1640 medium containing 10% human serum with or without TSG-6 (200
ng/ml). Cells were harvested for immunoblotting analysis for CD68 (differentiation marker), MARCO (M1 marker), or MRC1 (M2 marker). b-actin
served as a loading control. The graph shows the expressions of MARCO on day 6 and MRC1 on day 3. n ¼ 3; *p < 0.001 vs. 0 ng/ml of TSG-6.
(B) HMDMs differentiated by 10% human serum without TSG-6 were incubated for 26 h in serum-free RPMI-1640 medium with or without
TSG-6 (300 ng/ml). The concentrations of IL-6 and TNF-a in culture supernatants were measured by enzyme-linked immunosorbent assay.
Baseline of control ¼ 27.3  11.9 pg/ml (IL-6) and 34.7  3.1 pg/ml (TNF-a). n ¼ 3; †p ¼ 0.028 vs. control. (C) Human monocytes were
incubated to differentiate into HMDMs for 7 days in RPMI-1640 with 10% human serum and the indicated concentrations of TSG-6, followed by
a further 19 h with the same concentrations of TSG-6, 50 mg/ml oxLDL, and 0.1 mmol/l [3H]oleate. Foam cell formation was determined from
the intracellular radioactivity of cholesterol-[3H]oleate. Baseline of control ¼ 11.8  4.0 nmol/mg cell protein. n ¼ 4; ‡p ¼ 0.042 vs. 0 ng/ml of
TSG-6. (D to F) Before the addition of oxLDL, HMDMs were harvested for immunoblotting analysis of CD36, ACAT1, or ABCA1. b-actin served as
a loading control. n ¼ 6 to 7; #p ¼ 0.021; §p ¼ 0.014; ¶p < 0.01; and＠p < 0.001 vs. 0 ng/ml of TSG-6. All values are presented as mean 
SEM. ACAT1 ¼ acyl-CoA:cholesterol acyltransferase-1; oxLDL ¼ oxidized low-density lipoprotein; other abbreviations as in Figure 1.
Watanabe et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6
TSG-6 Suppresses Atherosclerosis O C T O B E R 2 0 1 6 : 4 9 4 – 5 0 9
500monocyte differentiation into HMDMs. However,
TSG-6 signiﬁcantly decreased the expression of
MARCO, an M1 marker, on day 6 and showed a
tendency to increase the expression of MRC1, an M2
marker, only on day 3 but not on day 6. These obser-
vations indicated that TSG-6 shifted the macrophage
phenotype overwhelmingly to M2 rather than M1.
As shown in Figure 2B, TSG-6 showed a tendency to
suppress IL-6 secretion and signiﬁcantly suppressed
TNF-a secretion from HMDMs. However, TSG-6
did not signiﬁcantly suppress the LPS-induced IL-6
and TNF-a secretion from HMDMs (Supplemental
Figure 1).EFFECTS OF TSG-6 ON FOAM CELL FORMATION IN
HMDMs. TSG-6 signiﬁcantly suppressed oxLDL-
induced foam cell formation by 25% at 50 ng/ml in
HMDMs (Figure 2C). In HMDMs just before oxLDL
was added, TSG-6 signiﬁcantly suppressed CD36 and
ACAT1 protein expression (Figures 2D and 2E) and
showed a tendency to increase ABCA1 protein
expression (Figure 2F) in a concentration-dependent
manner.
EFFECTS OF TSG-6 ON MIGRATION AND PROLIFERATION
IN HUMAN VSMCs. TSG-6 signiﬁcantly suppressed
the proliferation of HASMCs in a concentration-
dependent manner, with the maximal reduction by
FIGURE 3 Effects of TSG-6 on Proliferation, Migration, and Signal Transduction in Human VSMCs
(A) Proliferation of HASMCs was determined by WST-8 assay after 48-h incubation in conditioned medium with the indicated concentrations
of TSG-6. HASMCs were stained with Giemsa. n ¼ 5; *p ¼ 0.035; †p ¼ 0.029; ‡p < 0.0001 vs. 0 ng/ml of TSG-6. (B) Migration of
HASMCs was determined in 10 cells/well using a BIOREVO BZ-9000 microscope in serum-free medium with or without AngII (500 nmol/l)
and/or TSG-6 (300 ng/ml). n ¼ 30 from 3 independent experiments. #p < 0.0001. (C) To assess their signal transductions, HASMCs that were
incubated for 48 h with or without TSG-6 (300 ng/ml) were subjected to immunoblotting analysis for PI3K, c-Src, Raf-1, phosphorylated
ERK1/2, JNK, and NF-kB. a-tubulin served as a loading control. n ¼ 3 to 4; §p ¼ 0.035; ¶p ¼ 0.020; ＠p ¼ 0.013 vs. 0 ng/ml of TSG-6.
All values are presented as mean  SEM. AngII ¼ angiotensin II; NF-kB ¼ nuclear factor–kB; p-ERK ¼ phosphorylated ERK; PI3K ¼
phosphoinositide 3-kinase; VSMC ¼ vascular smooth muscle cell; other abbreviations as in Figure 1.
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cell number was not attributed to death due to
apoptosis and cytotoxicity by 300 ng/ml TSG-6
(Figure 3A). In addition, the migration of HASMCswas signiﬁcantly increased by the treatment with
500 nmol/l AngII (Figure 3B). However, TSG-6 sig-
niﬁcantly suppressed the AngII-induced migration
of HASMCs (Figure 3B).
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502TSG-6 signiﬁcantly suppressed the protein
expression of c-Src, JNK, and NF-kB, but not PI3K,
Raf-1, and phosphorylated ERK1/2 in HASMCs
(Figure 3C). As exhibited in Supplemental Figure 2A,
TSG-6 increased the protein expression of Bcl-2, an
antiapoptotic molecule, and decreased that of p38,
a proapoptotic molecule, without affecting both
contractile and synthetic phenotypes (a-SMA and
SMemb) in HASMCs.
EFFECTS OF TSG-6 ON ECM EXPRESSION AND
ACTIVITY IN HUMAN VSMCs. TSG-6 signiﬁcantly
increased the protein expression of collagen-1,
collagen-3, MMP-2, and TIMP-2 and showed a ten-
dency to increase MMP-9, ﬁbronectin, and elastin inFIGURE 4 Effects of TSG-6 on ECM Expression in Human VSMCs
(A) HASMCs were incubated for 24 h with the indicated concentrations
collagen-1, collagen-3, TIMP-2, MMP-2, MMP-9, ﬁbronectin, elastin, and
molecule. (Bottom) Densitometric data of each molecule after normaliz
‡p ¼ 0.047; #p < 0.01 vs. 0 ng/ml of TSG-6. (B) HASMCs were incuba
concentrations of TSG-6. In the culture supernatant, MMP-2 and -9 act
§p ¼ 0.049; ¶p ¼ 0.031; ＠p ¼ 0.011; &p < 0.0001 vs. 0 ng/ml of TS
matrix; M ¼ matrix metalloproteinase marker; MMP ¼ matrix metallopr
VSMC ¼ vascular smooth muscle cell; other abbreviations as in Figure 1HASMCs (Figure 4A). Further, TSG-6 signiﬁcantly
increased the activities of MMP-2 and -9 in a
concentration-dependent manner (Figure 4B).
EFFECTS OF TSG-6 ON ATHEROSCLEROTIC LESION
DEVELOPMENT IN ApoEL/L MICE. In 21-week-old
compared with 17-week-old ApoE/ mice, aortic
atherosclerotic lesions in both the entire surface area
and the cross-sectional area of the sinus (plaque size)
signiﬁcantly developed by 2-fold (Figures 5A, 5B, 5D,
5E, 5S, and 5T), whereas body weight signiﬁcantly
increased by 15% (Table 2). At 21 weeks of age, TSG-6
levels in plasma were signiﬁcantly increased by
1.6-fold in TSG-6–infused mice compared with their
saline-infused counterparts (Table 2). Chronicof TSG-6 and were harvested for immunoblotting analyses of
a-tubulin. (Top) Representative results of protein expression of each
ation relative to a-tubulin. n ¼ 4 to 7; *p ¼ 0.025; †p ¼ 0.015;
ted for 24 h in serum-free conditioned medium with the indicated
ivities were determined by the gelatin zymography. n ¼ 5 to 6;
G-6. All values are presented as mean  SEM. ECM ¼ extracellular
oteinase; S ¼ sample; TIMP ¼ tissue inhibitor of metalloproteinase;
.
FIGURE 5 Effects of TSG-6 on Atherosclerotic Lesion Development in ApoE/ Mice
Among 28 ApoE/ mice at 17 weeks of age, 6 mice were sacriﬁced before infusion, and 13 and 9 mice were infused with saline (control) or TSG-6 (75 ng/kg/min),
respectively, by osmotic minipumps for 4 weeks. The aortic surface was stained by oil red O (A to C). Cross sections of the aortic sinus were stained with oil red O (D to F);
antibodies of MOMA-2, a monocyte-macrophage marker (G to I); pentraxin-3, a vascular inﬂammation marker (J to L); a-SMA, a VSMC marker (M to O); and Masson’s
trichrome, a collagen ﬁber marker (P to R). Hematoxylin was used for nuclear staining. (S to X) Comparisons of atherosclerotic lesion area, plaque size, intraplaque
monocyte/macrophage and VSMC contents, vascular inﬂammation, and collagen ﬁbers among the 3 groups. *p < 0.001; ‡p < 0.01; #p ¼ 0.022 vs. 17-week control;
†p ¼ 0.024; §p < 0.005 vs. 21-week control. All values are presented as mean  SEM. ApoE/ ¼ apolipoprotein E deﬁcient; Cont ¼ control; SMA ¼ smooth muscle
actin; TSG ¼ tumor necrosis factor–stimulated gene; VSMC ¼ vascular smooth muscle cell.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6 Watanabe et al.
O C T O B E R 2 0 1 6 : 4 9 4 – 5 0 9 TSG-6 Suppresses Atherosclerosis
503infusion of TSG-6 signiﬁcantly retarded the surface
areas of the atherosclerotic lesions by 30%
(Figures 5B, 5C, and 5S), with little reduction of plaque
size in the sinus (Figures 5E, 5F, and 5T). In the
atherosclerotic plaque, there was a signiﬁcant
reduction of monocyte/macrophage inﬁltration
(Figures 5H, 5I, and 5U). TSG-6 was prone to
decreasing vascular inﬂammation (Figures 5K, 5L, and
5V) and VSMC contents (Figures 5N, 5O, and 5W) along
with increasing collagen ﬁbers (Figures 5Q, 5R, and 5X).
Chronic infusion of TSG-6 signiﬁcantly decreased
cell number (Table 2), and protein expression
of MARCO (M1 marker), MCP-1, COX-2, NF-kB,and phosphorylated ERK1/2, but not arginase-1
(M2 marker) in peritoneal exudate macrophages
(Figure 6). TSG-6 also showed a tendency to decrease
pentraxin-3 and JNK expression (Figure 6). As
exhibited in Supplemental Figure 2B, TSG-6
suppressed other inﬂammatory molecules such
as C-reactive protein (CRP), apoptosis-associated
speck-like protein containing a caspase recruitment
domain, and TNF-a–induced protein-1.
There were no signiﬁcant differences in body
weight, systolic and diastolic blood pressures, or
plasma levels of glucose and pentraxin-3 between the
2 groups of ApoE/ mice at 21 weeks of age (Table 2).
TABLE 2 Characteristics and Laboratory Data of ApoE/ Mice
17-Week Controls
(n ¼ 6)
21-Week Controls
(n ¼ 13)
TSG-6
(n ¼ 9)
Body weight, g 26.7  0.7 30.5  0.4* 31.0  0.7*
Systolic blood pressure, mm Hg 106.2  5.6 94.0  2.3 106.6  3.7
Diastolic blood pressure, mm Hg 84.2  6.1 74.9  2.6 76.8  5.4
TSG-6, ng/ml 0.97  0.16 1.00  0.10 1.59  0.26†
Glucose, mg/dl 173.3  13.1 206.3  25.0 186.8  10.0
Total cholesterol, mg/dl 1,639.5  68.5 1,766.3  64.8 1,572.2  52.8‡
HDL cholesterol, mg/dl 6.68  1.50 6.55  1.05 8.48  1.31
Pentraxin-3, ng/ml 111.8  26.9 108.6  6.7 116.8  9.8
Peritoneal exudate cells,  107 NE 0.56  0.02 0.23  0.06§
Values are mean  SEM. *p < 0.005 vs. 17-week controls; †p ¼ 0.033; ‡p ¼ 0.043; §p < 0.005 vs. 21-week
controls.
ApoE/ ¼ apolipoprotein E deﬁcient; HDL ¼ high-density lipoprotein; NE ¼ not examined; TSG ¼ tumor
necrosis factor–stimulated gene.
FIGURE 6 Effects of TSG-6 on Inﬂammatory Phenotype and Marker
Peritoneal cells obtained from ApoE/ mice were suspended in conditi
2 ml/dish). After incubation for 1 h at 37C in 5% CO2 to allow adhesion,
adherent macrophages were harvested after washing the dishes with pho
(M1 marker), arginase-1 (M2 marker), MCP-1, pentratin-3, COX-2, NF-kB,
n ¼ 3 to 5; *p ¼ 0.018; †p ¼ 0.031; ‡p ¼ 0.012; #p ¼ 0.041; §p ¼ 0.03
Abbreviations as in Figures 3 and 5.
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504However, TSG-6 signiﬁcantly decreased plasma total
cholesterol levels and showed a tendency to increase
HDL cholesterol levels.
PRESENCE OF TSG-6 IN HUMAN CORONARY ARTERY
LESIONS AND PLASMA. The levels of TSG-6 expres-
sion were assessed in human coronary arteries from 4
patients without CAD and 13 with CAD. Expression of
TSG-6 was minimal in normal and nonstenotic coro-
nary arteries from a patient without CAD and a pa-
tient with CAD, respectively (Figures 7A to 7D). In the
stenotic coronary artery from another patient with
CAD, TSG-6 was highly expressed in the ﬁbrous cap
within atherosclerotic plaques (Figures 7E and 7F),
which were indicated by consistent areas stained
blue with Masson’s Trichrome (Figure 7H). The
remaining patients with and without CAD showed
similar results.Expression in Peritoneal Exudate Macrophages From ApoE/ Mice
oned medium and seeded onto 6-cm dishes (4  106 cells per
the medium was discarded to remove nonadherent cells. Immediately,
sphate-buffered saline twice for immunoblotting analyses of MARCO
JNK, and phosphorylated ERK1/2. b-actin served as a loading control.
8; ¶p < 0.0001 vs. control. All values are presented as mean  SEM.
FIGURE 7 Expression of TSG-6 in Human Coronary Arteries From Patients Without and With CAD
Representative normal coronary arteries (A and B) from a patient with dilated cardiomyopathy (male, age 34 years) and nonstenotic coronary
arteries (C and D) from a patient with previous myocardial infarction (male, age 78 years), and representative stenotic coronary arteries (E to I)
from a patient with previous myocardial infarction (male, age 62 years) were stained with anti–TSG-6 antibody (A to F); anti-a-SMA antibody,
a VSMC marker (G); Masson’s Trichrome, a collagen ﬁber marker (H); and anti-CD68 antibody, a macrophage marker (I). These patients died of
heart failure or stroke. All coronary arteries were not the culprit artery of acute coronary events. CAD ¼ coronary artery disease; other ab-
breviations as in Figure 5.
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505Next, plasma TSG-6 levels were compared be-
tween 47 patients without CAD and 135 patients
with CAD. As listed in Table 3, age; prevalence of
smoking, diabetes, and hypertension; and use of
antidiabetic drugs were signiﬁcantly greater and
HDL cholesterol levels were signiﬁcantly lower in
patients with CAD than in subjects without CAD.
The prevalence of several kinds of antihyperten-
sive and antidyslipidemia drugs, and LDL choles-
terol levels did not differ signiﬁcantly between the
2 groups. As shown in Figure 8, plasma TSG-6
levels were signiﬁcantly higher in patients with
CAD than in subjects without CAD. Because a
previous report showed increased TSG-6 levels in
the airway secretions of smokers (28), we evalu-
ated the relationship between plasma TSG-6 levelsand smoking in patients without and with CAD.
Plasma TSG-6 levels did not differ signiﬁcantly
between smokers and nonsmokers both in the non-
CAD group (6.72  1.24 vs. 7.89  1.21; p ¼ 0.693)
and the CAD group (13.00  0.93 vs. 10.90  1.24;
p ¼ 0.202). In all subjects (n ¼ 182), multiple linear
regression analysis revealed that plasma TSG-6
levels were not signiﬁcantly associated with age,
and the prevalence of male, smoking, diabetes, and
hypertension (all p > 0.05). Pearson’s regression
analysis conﬁrmed no signiﬁcant correlations of
plasma TSG-6 levels with age (r ¼ 0.142; p ¼ 0.056;
n ¼ 182) or high-sensitivity CRP (r ¼ 0.033;
p ¼ 0.682; n ¼ 161). These ﬁndings suggest that
TSG-6 in plasma may be a candidate for an inde-
pendent biomarker of CAD.
TABLE 3 Patient Characteristics
Non-CAD Subjects
(n ¼ 47)
CAD Patients
(n ¼ 135) p Value
Male 68.1 75.6 0.317
Age, yrs 47.3  2.5 70.8  1.1 <0.0001
Smoking 14.9 69.6 <0.0001
Diabetes 8.5 31.1 0.002
Hypertension 53.2 72.6 0.014
Dyslipidemia 17.4 25.4 0.269
Antidiabetic drugs 2.1 17.2 0.009
ARBs 36.2 33.6 0.748
ACE inhibitors 0.0 4.5 0.140
Calcium-channel blockers 23.9 32.1 0.296
Beta-blockers 6.4 9.0 0.582
Statins 14.9 19.4 0.491
Fibrates 2.1 1.5 0.774
Eicosapentaenoic acids 4.3 4.5 0.942
LDL cholesterol, mg/dl 122.6  5.06* 115.6  3.09 0.291
HDL cholesterol, mg/dl 57.70  1.97* 44.50  0.95 <0.0001
Values are % or mean  SEM. The p values in bold are statistically signiﬁcant. *n ¼ 34.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HDL ¼
high-density lipoprotein; LDL ¼ low-density lipoprotein.
FIGURE 8 Plasma TSG-6 Levels in Patients Without and
With CAD
Plasma TSG-6 levels were measured by enzyme-linked
immunosorbent assay in 47 subjects without CAD and 135
patients with acute coronary syndrome. *p < 0.005 vs. non-CAD.
All values are presented as mean  SEM. CAD ¼ coronary artery
disease; TSG-6 ¼ tumor necrosis factor–stimulated gene-6.
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506DISCUSSION
This is the ﬁrst demonstration that TSG-6 indeed
suppresses the inﬂammatory response and cell pro-
liferation in ECs, inﬂammatory phenotype and foam
cell formation in HMDMs, and migration and prolif-
eration of VSMCs in vitro. This study also showed that
TSG-6 retards the development of aortic atheroscle-
rotic lesions with decreased intraplaque contents of
monocytes/macrophages and VSMCs in ApoE/ mice
in vivo. However, atherosclerotic plaque size in the
aortic sinus was not completely suppressed by TSG-6.
In our ﬁndings, TSG-6 increased collagen-1 and -3
expression in vitro and collagen ﬁbers in atheroscle-
rotic plaques in vivo, and TSG-6 was expressed at
high levels in the ﬁbrous cap within human coronary
atherosclerotic plaques, which suggests that TSG-6
contributes to the stability of atherosclerotic pla-
ques. Plasma TSG-6 levels are speculated to increase
in patients with CAD, because chronic vascular
inﬂammation stimulates TSG-6 production to coun-
teract atherogenesis. Further analyses are required to
clarify the relationship of decreased TSG-6 expression
levels in the coronary plaque tissue and/or the circu-
lating blood with plaque destabilization and rupture.
TSG-6 expression in macrophages, VSMCs, and
ﬁbroblasts was enhanced by LPS, FGF, and trans-
forming growth factor-b (1). TSG-6 was also detected
in the serum of patients with systemic lupus ery-
thematosus and bacterial sepsis and of volunteersinjected with bacterial LPS (29). Reportedly, TSG-6
contributes to stabilize murine eye lesions by its
anti-inﬂammatory properties (30,31). Moreover, TSG-
6 ampliﬁes hyaluronan synthesis in murine airway
SMCs (32). A previous study showed that TSG-6 ex-
erts an anti-inﬂammatory function by counteracting
the transcription of MMP-1 and -3 and the activation
of MMP-1 in human ﬁbroblasts (33). In the present
study, up-regulation of collagens and MMPs by TSG-6
in VSMCs may be associated with vascular tissue
injury, repair, and regeneration with inﬂammation
(34). TSG-6 was shown to exert anti-inﬂammatory
effects in several animal models. Administration of
TSG-6 improved arthritis and diminished inﬂamma-
tion in several murine models (2,35). Our study
showed that chronic TSG-6 infusion into ApoE/
mice suppressed pentraxin-3 expression in aortic
tissues and exudate peritoneal macrophages but
not in plasma. In transgenic mice, knockout of the
gene aggravated inﬂammatory responses (36), and
overexpression of the gene decreased inﬂammatory
responses (37). Further studies are needed to eluci-
date whether knockout of TSG-6 in ApoE/mice may
accelerate the progression of atherosclerotic lesions.
The present results concerning the effect of TSG-6
on VSMC proliferation are inconsistent with a previ-
ous report. Ye et al. (12) showed that both rabbit
aortic VSMCs and rat pulmonary VSMCs with over-
expressing TSG-6 exhibited an increase in cell
number in the serum-free culture system (12). In our
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507WST-8 assay, TSG-6 signiﬁcantly suppressed HASMC
proliferation in a concentration-dependent manner in
a standard medium containing 5% FBS. The differ-
ence may be attributed to differences in species,
methods of adding TSG-6 into cells, and presence or
absence of sera. Our examination may be performed
in human cells under more physiological conditions.
However, TSG-6 did not signiﬁcantly suppress
HASMC proliferation induced by platelet-derived
growth factor-BB in our preliminary examination
(data not shown).
The speciﬁc receptors for TSG-6 have not yet
been identiﬁed. It is especially important to elucidate
the putative receptor, which provides an investiga-
tion of its agonist as a new drug target to treat
atherosclerosis. The signal transduction pathways
for TSG-6 have also been rarely reported. The present
study suggests that TSG-6 suppresses the migration
and proliferation of VSMCs via the down-regulation
of c-Src, JNK, and NF-kB but may not induce
apoptosis via both the up-regulation of Bcl-2, an
antiapoptotic molecule, and the down-regulation
of p38, a proapoptotic molecule (Supplemental
Figure 2A). As exhibited in Supplemental Figure 3,
the down-regulation of ERK1/2 may participate in the
signals of which TSG-6 causes an M1 to M2 phenotype
transition during the differentiation of human
monocytes into macrophages (38). In mouse exudate
macrophages, TSG-6 suppressed M1 phenotype and
MCP-1 and COX-2 expression associated with the
down-regulation of ERK1/2 and NF-kB.
We discuss the integrity of TSG-6 concentrations in
our in vitro and in vivo experiments. First, the con-
centrations of TSG-6 required to modulate several
responses of HMDMs, human ECs, and HASMCs were
considerably high: 10- to 60-fold higher than plasma
TSG-6 levels in humans (w5 ng/ml). In the vascular
wall, large amounts of TSG-6 are mainly generated by
vascular cells other than ﬁbroblasts in an autocrine/
paracrine manner. Animal and clinical studies
showed that local levels of other vasoactive agents
such as serotonin and AngII were increased by 10- to
100-fold with coronary events in obstructive arteries
and cardiac interstitial ﬂuid (39,40), which is com-
parable with the present study. Second, the TSG-6
level in human serum from a healthy volunteer was
7.4 ng/ml in the present study. Therefore, the 10%
concentration added to the culture medium for
human monocyte-macrophages (0.74 ng/ml) was
negligible compared with the concentrations of
human recombinant TSG-6 that were added. Third,
the adequate concentrations of TSG-6 differed in
inducing foam cell formation and related proteinexpression inHMDMs. This ismostly dependent on the
difference in the presence or absence of oxLDL and
their concerned signal transductions. TSG-6 at greater
than adequate concentrations might lead to the down-
regulation of the receptor and intracellular signals.
Last, plasma TSG-6 levels in ApoE/ mice infused
with TSG-6 became signiﬁcantly higher (w1.6 fold)
than those of ApoE/mice infused with saline, which
were not as high as expected. The peptide might be
somewhat metabolized in circulating blood.
In the present study, other than the atheropro-
tective effects of TSG-6 in vitro, an important unex-
pected effect was observed in vivo. Chronic
TSG-6 infusion in ApoE/ mice signiﬁcantly de-
creased plasma total cholesterol levels with a slight
increase in HDL cholesterol levels. We speculate
that TSG-6 may decrease intestinal cholesterol
absorption, hepatic synthesis, and the assembly of
very-low-density lipoprotein. In addition, it may
increase hepatic LDL receptor expression, leading
to a decrease in total cholesterol levels. Taken
together, these ﬁndings may strengthen the clinical
utility of TSG-6 in the prevention and treatment of
atherosclerosis.
CONCLUSIONS
The present results indicate that TSG-6 retards the
development of atherosclerotic lesions by decreasing
plasma total cholesterol levels, inﬂammatory re-
sponses of ECs and HMDMs, macrophage foam cell
formation, and the migration and proliferation of
VSMCs. In addition, TSG-6 counteracts atherogenesis
and contributes to plaque stability by promoting the
production of collagen in the ﬁbrous cap. Thus, TSG-6
replacement therapy, with either the peptide itself
and/or its analogues, is expected to emerge as a new
line of therapy against atherosclerosis and its related
CAD. The results presented here also provide insights
into the potential use of TSG-6 as a biomarker for
CAD. These ﬁndings may strengthen the clinical
utility of TSG-6 in the diagnosis and treatment
of CAD.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: TSG-6 is
regarded as an anti-inﬂammatory protein. Our cellular,
animal, and clinical experiments demonstrate the pro-
tective effects of TSG-6 against vascular inﬂammation
and atherosclerosis. TSG-6 also contributes to the sta-
bility of atherosclerotic plaques. Thus, TSG-6 may open a
new therapeutic window for combating atherosclerosis
and related CAD. In addition, our study provides insights
into the potential use of TSG-6 as a biomarker for CAD.
TRANSLATIONAL OUTLOOK: The present study is
the ﬁrst to show that TSG-6 could be a candidate
biomarker and therapeutic target for atherosclerotic
cardiovascular diseases. Prospective studies concerning
the clinical utility of TSG-6 in the diagnosis and
treatment of CAD and outcomes over time may be
warranted.
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